F-Box Protein-Mediated Resistance to PARP Inhibitor Therapy
Aleksandra I Adamovich1, Amanda Ewart Toland2, Jeffrey D Parvin1
1Department of Biomedical Informatics, The Ohio State University and The OSU Comprehensive Cancer Center, Columbus, OH, USA.
Abstract:
PARP inhibitor (PARPi) therapy targets BRCA1/2 mutant tumor cells, but acquired resistance limits its effectiveness. In this issue of Molecular Cell, Marzio et al. (2019) identify a novel mechanism of resistance to PARPi through regulation of RAD51 protein stability via an SCF ubiquitin ligase dependent on EMI1.
Insights
Scientists discovered a new way cancer cells resist PARP inhibitor (PARPi) therapy. Resistance occurs when EMI1 controls RAD51 protein stability, impacting tumor cell survival.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Poly (ADP-ribose) polymerase inhibitors (PARPi) are effective against tumors with BRCA1/2 mutations.
- Acquired resistance to PARPi therapy remains a significant clinical challenge.
- Understanding resistance mechanisms is crucial for improving cancer treatment.
Purpose of the Study:
- To identify novel mechanisms of acquired resistance to PARP inhibitors.
- To investigate the role of protein stability in PARPi resistance.
- To elucidate the molecular players involved in regulating resistance pathways.
Main Methods:
- Utilized cell-based assays to study PARPi resistance.
- Investigated the role of the SCF ubiquitin ligase complex.
- Examined the regulation of RAD51 protein stability.
Main Results:
- Identified a novel mechanism of PARPi resistance mediated by EMI1.
- Demonstrated that EMI1 regulates RAD51 protein stability.
- Showcased the involvement of an SCF ubiquitin ligase complex in this process.
Conclusions:
- EMI1-dependent regulation of RAD51 stability is a key mechanism of acquired PARPi resistance.
- Targeting this pathway may offer new therapeutic strategies for overcoming resistance.
- Further research is warranted to explore clinical applications.
More Related Videos
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Gene Therapy
Receptor-mediated Endocytosis
Resistivity
Resistance
Equivalent Resistance


